Interpace Biosciences, Inc. - SIC # 8030 -

Ticker Exchange SIC # Website Latest Ticker
IDXG Over the counter 8030 www.interpace.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Interpace Biosciences, Inc.

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results - Nov 4th, 2024 9:30 pm
Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq - Oct 15th, 2024 8:05 pm
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results - Aug 1st, 2024 8:30 pm
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts - Jul 29th, 2024 12:25 pm
Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract - Jun 4th, 2024 12:00 pm
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results - May 9th, 2024 8:01 pm
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results - Mar 7th, 2024 1:00 pm